The 7th U-PGx Personalized Medicine Day will be organized in Ljubljana, Slovenia on March 24th, 2021.
The meeting will be co-organized by the Golden Helix Foundation and the University of Ljubljana, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353). This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
In light of the coronavirus pandemic, the U-PGx Executive Board has made the decision to hold the 7th U-PGx Personalized Medicine Day as a VIRTUAL meeting and the meeting will start at 9 am CET.
We look forward to a successful meeting.
On behalf of the Organizing Committee
Co-organized by:
Funded by:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353.
IntroductionAbout U-PGxSpeakersScientific ProgramThe 7th U-PGx Personalized Medicine Day will be organized in Ljubljana, Slovenia on March 24th, 2021.
The meeting will be co-organized by the Golden Helix Foundation and the University of Ljubljana, both partners of the Ubiquitous Pharmacogenomics (U-PGx) project, funded by the European Commission (H2020-668353). This international event is open for clinical pharmacologists, hospital pharmacists, general pharmacists, specialists, general practitioners, medical students, laboratory technicians, regulators, healthcare insurers and others interested in pharmacogenomics.
In light of the coronavirus pandemic, the U-PGx Executive Board has made the decision to hold the 7th U-PGx Personalized Medicine Day as a VIRTUAL meeting and the meeting will start at 9 am CET .
We look forward to a successful meeting.
On behalf of the Organizing Committee
Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.
Organizing Committee
Vita Dolzan (Ljubljana, SI)
Christina Mitropoulou (London, UK)
Local Organizing Committee
Vita Dolžan, Tanja Blagus, Katja Goričar
University of Ljubljana, Faculty of Medicine,
Department of Biochemistry and Molecular Genetics,
Pharmacogenetics Laboratory, Ljubljana, Slovenia
Invited Speakers
Vita Dolžan, University of Ljubljana, Faculty of Medicine, Institute of BIochemistry and Molecular Genetics, Pharmacogenetics Laboratory
Tanja Blagus, University of Ljubljana, Faculty of Medicine, Institute of BIochemistry and Molecular Genetics, Pharmacogenetics Laboratory
Henk Jan Guchelaar, Leiden University Medical Center, Dept. Clinical Pharmacy & Toxicology, Leiden, The Netherlands
Jesse J. Swen, Leiden University Medical Center, Dept. Clinical Pharmacy & Toxicology, Leiden, The Netherlands
Magnus Ingelman-Sundberg, Karolinska Institutet, Department of Physiology and Pharmacology, Section of pharmacogenetics, Stockholm, Sweden
Borut Peterlin, University Medical Center Ljubljana Clinical Institute of Medical Genetics, Ljubljana, Slovenia
Gorazd Hladnik, Provita d.o.o., Ljubljana, Slovenia
Gregor Mlinšek, University Medical Center Ljubljana, Department of Urology, Ljubljana, Slovenia
Nada Božina, University Hospital Centre Zagreb, Department of Laboratory Diagnostics, Division of Pharmacogenomics and Therapy Individualisation and School of Medicine University of Zagreb, Department of Pharmacology, Zagreb, Croatia
Branka Zukić, University of Belgrade, Institute of Molecular Genetics and Genetic Engineering, Laboratory for Molecular Biomedicine, Belgrade, Serbia
Erica Cecchin, Centro di Riferimento Oncologico, IRCCS, Farmacologia Sperimentale e Clinica, Aviano, Italy
Barbara Mazej Poredoš, Health Care Center Ljubljana, Ljubljana, SloveniaGorazd Hladnik, Provita, d.o.o., Ljubljana, SloveniaGregor Mlinšek, University Medical Centre Ljubljana, Department of Urology, Ljubljana, Slovenia
Janja Marc, University of Ljubljana, Faculty of Pharmacy, Department of Clinical Biochemistry, Ljubljana, Slovenia
Uroš Potočnik, University of Maribor, Faculty of Medicine, Center for Human Molecular Genetics and Pharmacogenomics, Maribor, Slovenia
Jasna Klen, University Medical Centre Ljubljana, Division of surgery, Department of abdominal surgery, Ljubljana, Slovenia
09:00 – 09:15 Opening statements
Vita Dolzan, Faculty of Medicine, University of Ljubljana
Dean, Faculty of Medicine, University of Ljubljana
Medical Director, Faculty of Medicine, University of Ljubljana
PLENARY SESSION I: Pre-emptive pharmacogenomics tasting and the U-PGx project
09:15 – 09:45 Pre-emptive pharmacogenomics testing and the U-PGx project
Henk-Jan Guchelaar
09:45 – 10:15 The Dutch Pharmacogenetics Working Group guidelines: Putting pharmacogenetics into practice
Jesse Swen
10:15 – 10:45 PREPARE Study in Slovenia
Vita Dolzan, Tanja Blagus
10:45 – 11:00 Coffee Break
PLENARY SESSION II: Enabling Personalized Medicine
11:00 – 11:30 From genotyping to haplotyping in pharmacogenomics
Magnus Ingelman-Sundberg
11:30 – 11:50 Slovenian Genome Project
Borut Peterlin
11:50 – 12:10 Implementation of pharmacogenomics in clinical practice in Croatia
Nada Bozina
12:10 – 12:30 Pharmacogenomics in Serbia: From the bench to the bedside
Branka Zukic
12:30 – 13:00 Pharmacogenetics testing in oncology
Erika Cecchin
13:00 – 14:00 LUNCH BREAK
PLENARY SESSION III: Pharmacogenetics from research to clinical practice
14:00 – 14:20 Pharmacogenetics testing at the primary healthcare level
Barbara Mazej Poredos
14:20 – 14:40 From Personalized Medicine to mobile health management
Gorazd Hladnik
14:40 – 15:00 Pharmacogenetics testing in kidney transplantation medicine
Gregor Mlinsek
15:00 – 15:20 Pharmacogenetic testing in imatinib treatment
Janja Marc
15:20 – 15:40 Pharmacogenetic of asthma treatment
Uros Potocnik
15:40 – 16:00 Pharmacogenetics of diabetes treatment
Jasna Klen
16:00 – 16:15 Discussion and Concluding remarks
Vita Dolzan
* All times are Central European Time